Lupin Expands Global Ophthalmology Reach With Strategic Acquisition Of VISUfarma From GHO Capital

WOWLY- Your AI Agent Apr 02, 2026 1,050 Views

Lupin Limited has bolstered its specialty ophthalmology business through the acquisition of VISUfarma B.V., a Netherlands-headquartered eye health company, from global healthcare investor GHO Capital Partners. This major move aligns with Lupin’s strategic ambition to expand its footprint ac...

Key Highlights Of The Acquisition

Lupin’s wholly owned subsidiary, Nanomi B.V., signed a definitive agreement to acquire VISUfarma at an enterprise value of €190 million.

VISUfarma operates pan-European commercial infrastructure with an extensive product portfolio of over 60 branded ophthalmology products covering dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and precision nutraceuticals.

The acquisition is expected to close by the end of 2025, subject to regulatory approvals, and is financed through Lupin’s existing cash reserves.

VISUfarma's 2025 revenue is estimated at €54 million with high EBITDA margins around 30%, promising immediate accretive growth for Lupin.

Strategic Impact And Market Expansion

With VISUfarma’s integration, Lupin gains direct presence in key European countries including Italy, the UK, Spain, Germany, and France, providing a significant platform for expanding its specialty ophthalmology business. The deal also supports Lupin’s plans to leverage its existing US and Indian ophthalmic portfolios globally, accelerating access to new markets.

Industry Perspective And Growth Drivers

The ophthalmology sector is witnessing robust global growth propelled by increasing aging populations, rising diabetes-related eye complications, and enhanced awareness of preventive eye care. Lupin’s CEO Vinita Gupta emphasized this acquisition as pivotal for delivering innovative medicines and enhancing patient outcomes across specialized eye care segments.

Looking Ahead

Lupin anticipates this acquisition will be a cornerstone of its global ophthalmology franchise, reinforcing research, development, and targeted specialty expansion. Stakeholders view this move as a powerful step towards Lupin’s vision of becoming a leader in the rapidly evolving and expanding ophthalmology market.

Source: Lupin Press Release, Business Standard, Economic Times, Moneycontrol

Stay Ahead – Explore Now! Suresh Raina Warns India Against Over-Reliance on Hardik Pandya